1. Home
  2. CGAU vs IRTC Comparison

CGAU vs IRTC Comparison

Compare CGAU & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centerra Gold Inc.

CGAU

Centerra Gold Inc.

N/A

Current Price

$20.75

Market Cap

4.4B

ML Signal

N/A

Logo iRhythm Technologies Inc.

IRTC

iRhythm Technologies Inc.

N/A

Current Price

$126.32

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CGAU
IRTC
Founded
2002
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
3.7B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
CGAU
IRTC
Price
$20.75
$126.32
Analyst Decision
Buy
Strong Buy
Analyst Count
6
16
Target Price
$22.99
★ $171.33
AVG Volume (30 Days)
★ 981.8K
457.4K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 1.00%
N/A
EPS Growth
N/A
★ 61.71
EPS
★ N/A
N/A
Revenue
N/A
★ $747,138,000.00
Revenue This Year
$36.51
$19.35
Revenue Next Year
N/A
$16.58
P/E Ratio
$11.74
★ N/A
Revenue Growth
N/A
★ 26.24
52 Week Low
$11.13
$100.70
52 Week High
$24.52
$192.47

Technical Indicators

Market Signals
Indicator
CGAU
IRTC
Relative Strength Index (RSI) 42.81 67.01
Support Level $15.06 $112.00
Resistance Level $21.17 $129.94
Average True Range (ATR) 0.79 4.25
MACD -0.11 1.76
Stochastic Oscillator 38.19 91.14

Price Performance

Historical Comparison
CGAU
IRTC

About CGAU Centerra Gold Inc.

Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.

About IRTC iRhythm Technologies Inc.

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Share on Social Networks: